Cytograft Tissue Engineering, Inc. to Present at Medtech Insight and Windhover Information's ``Investment In Innovation (In3) WEST'' Conference, February 23-24, 2006, Irvine, Calif.IRVINE, Calif. -- Cytograft Tissue Engineering, Inc. has announced that it will be presenting on February 23rd, 2006 at 9:20 a.m. at Medtech Insight and Windhover wind·hov·er n. Chiefly British A kestrel. Information's "Investment In Innovation (In3) WEST: A Preview of Early-Stage Medical Technology Companies" Conference, February 23-24, 2006, at the Hyatt Regency Irvine in Irvine, Calif. Cytograft Tissue Engineering produces completely autologous autologous /au·tol·o·gous/ (aw-tol´ah-gus) related to self; belonging to the same organism. au·tol·o·gous adj. 1. cardiovascular repair products and is the clear leader in the field of Cardiovascular Tissue Engineering. The Company's lead product, the Lifeline(TM) small diameter blood vessel blood vessel n. An elastic tubular channel, such as an artery, a vein, a sinus, or a capillary, through which the blood circulates. blood vessel(s), n the network of muscular tubes that carry blood. , is the first lab-grown vessel to be used in adult humans for arterial revascularization. Cytograft's technology is targeted at four patient indications: A-V A-V abbr. 1. arteriovenous 2. atrioventricular A-V, AV 1. arteriovenous. 2. atrioventricular. A-V Atrioventricular, also 1. Anteversion 2. Aortic valve 3. shunts for hemodialysis access, lower limb revascularization for amputation amputation (ăm'pyətā`shən), removal of all or part of a limb or other body part. Although amputation has been practiced for centuries, the development of sophisticated techniques for treatment and prevention of infection has greatly candidates, coronary revascularization for coronary arterial bypass revision candidates and reconstruction of congenital defects in the heart for pediatric patients. These markets cumulatively represent an addressable Reachable. When something is addressable, it can be identified and manipulated independently of its surroundings. For example, screen pixels and RAM memory are addressable. Each of the screen's picture elements can be individually turned on and off, and each of the memory's bytes can be market of over $1B. Cytograft's platform technology, called sheet-based tissue engineering, produces robust tissues assembled exclusively from the patient's own cells. No synthetic scaffolds are used. The Lifeline(TM) graft is a living, viable tissue with mechanical properties similar to that of native vessels. The vessel is fully endothelialized and, as such, addresses the known failure modes associated with synthetic grafts. In November of 2005 at the American Heart Association American Heart Association (AHA), n.pr a national voluntary health agency that has the goal of increasing public and medical awareness of cardiovascular diseases and stroke, and thereby reducing the number of associated deaths and disabilities. annual meeting, the Company announced the first ever use of a laboratory-produced blood vessel for adult human bypass. The Lifeline(TM) graft was placed into the arms of 2 patients for hemodialysis access. With time points out to 9 months, the Lifeline(TM) grafts are patent without failure or intervention. This feasibility study represents a new hope for patients lacking suitable graft material due to previous harvest or disease progression. Cytograft is currently enrolling approximately 300 patients in a multi-center, randomized ran·dom·ize tr.v. ran·dom·ized, ran·dom·iz·ing, ran·dom·iz·es To make random in arrangement, especially in order to control the variables in an experiment. trial to support regulatory requirements for commercialization. A division of Windhover Information Inc., Medtech Insight is the leading provider of business information and market intelligence for the medical technology marketplace. In3 WEST is Medtech Insight's 20th investment and partnering event to date. To register to attend or for more information on Medtech Insight, please call Kristy Grimes at 480-985-9512 or 888-202-5939 toll-free in the U.S., e-mail kristy@medtechinsight.com, or visit www.medtechinsight.com. |
|
Printer friendly
Cite/link
Email
Feedback
Reader Opinion